Drug Trial Radar · NCT01018992
Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
Last checked: Nov 19, 2026Latest source record: Mar 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
267
Actual
Start
Dec 2009
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Icahn School of Medicine at Mount Sinai
- First posted
- Nov 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- Female only, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
Conditions
- Stress Disorders, Post-Traumatic
Interventions
GSK561679Drug
GSK561679, oral administration, 350mg/day, 6 week administration
PlaceboDrug
Matching placebo, oral administration, 1 pill/day for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) ScoreTime frame: Baseline, Week 6
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Stress and Health Research Program, San Francisco VA Medical Center, University of California San Francisco
San Francisco, California
Emory University
Atlanta, Georgia
Mount Sinai School of Medicine
New York, New York
Baylor College of Medicine
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.